ZA200506076B - Medicine for prevention of and treatment for arteriosclerosis and hypertension - Google Patents
Medicine for prevention of and treatment for arteriosclerosis and hypertension Download PDFInfo
- Publication number
- ZA200506076B ZA200506076B ZA200506076A ZA200506076A ZA200506076B ZA 200506076 B ZA200506076 B ZA 200506076B ZA 200506076 A ZA200506076 A ZA 200506076A ZA 200506076 A ZA200506076 A ZA 200506076A ZA 200506076 B ZA200506076 B ZA 200506076B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- substance
- composition
- treatment
- prophylaxis
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 139
- 239000003814 drug Substances 0.000 title claims description 80
- 206010020772 Hypertension Diseases 0.000 title claims description 41
- 230000002265 prevention Effects 0.000 title claims description 28
- 206010003210 Arteriosclerosis Diseases 0.000 title claims description 24
- 208000011775 arteriosclerosis disease Diseases 0.000 title claims description 24
- 229940079593 drug Drugs 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims description 423
- 239000000126 substance Substances 0.000 claims description 215
- 239000000203 mixture Substances 0.000 claims description 196
- 238000000034 method Methods 0.000 claims description 180
- -1 bamidipine Chemical compound 0.000 claims description 135
- 238000011321 prophylaxis Methods 0.000 claims description 125
- 238000004519 manufacturing process Methods 0.000 claims description 64
- 150000003839 salts Chemical class 0.000 claims description 53
- 239000000480 calcium channel blocker Substances 0.000 claims description 52
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 51
- 238000002360 preparation method Methods 0.000 claims description 43
- ZKFQEACEUNWPMT-UHFFFAOYSA-N Azelnidipine Chemical group CC(C)OC(=O)C1=C(C)NC(N)=C(C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-UHFFFAOYSA-N 0.000 claims description 42
- 229950004646 azelnidipine Drugs 0.000 claims description 42
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 41
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims description 37
- 239000004480 active ingredient Substances 0.000 claims description 36
- 230000005764 inhibitory process Effects 0.000 claims description 33
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 26
- 150000002148 esters Chemical class 0.000 claims description 23
- 210000004204 blood vessel Anatomy 0.000 claims description 21
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 21
- 208000034827 Neointima Diseases 0.000 claims description 20
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical class C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims description 19
- 230000008692 neointimal formation Effects 0.000 claims description 18
- 230000035755 proliferation Effects 0.000 claims description 16
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 15
- 208000037803 restenosis Diseases 0.000 claims description 15
- 208000032594 Vascular Remodeling Diseases 0.000 claims description 14
- 206010002383 Angina Pectoris Diseases 0.000 claims description 12
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 12
- 208000006029 Cardiomegaly Diseases 0.000 claims description 12
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 12
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 12
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 12
- 206010019280 Heart failures Diseases 0.000 claims description 12
- 206010042434 Sudden death Diseases 0.000 claims description 12
- 206010003119 arrhythmia Diseases 0.000 claims description 12
- 230000006793 arrhythmia Effects 0.000 claims description 12
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 208000019622 heart disease Diseases 0.000 claims description 12
- 208000010125 myocardial infarction Diseases 0.000 claims description 12
- 201000009925 nephrosclerosis Diseases 0.000 claims description 12
- 206010008118 cerebral infarction Diseases 0.000 claims description 11
- 208000017169 kidney disease Diseases 0.000 claims description 10
- 229960000528 amlodipine Drugs 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- SVJMLYUFVDMUHP-XIFFEERXSA-N (4S)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-[3-(4,4-diphenyl-1-piperidinyl)propyl] ester O3-methyl ester Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)OCCCN2CCC(CC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 SVJMLYUFVDMUHP-XIFFEERXSA-N 0.000 claims description 5
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 claims description 5
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 claims description 5
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 5
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 5
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 claims description 5
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 claims description 5
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 5
- FAIIFDPAEUKBEP-UHFFFAOYSA-N Nilvadipine Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 claims description 5
- 229950007556 aranidipine Drugs 0.000 claims description 5
- 229960004916 benidipine Drugs 0.000 claims description 5
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 claims description 5
- 229960003020 cilnidipine Drugs 0.000 claims description 5
- 229950003102 efonidipine Drugs 0.000 claims description 5
- 229960003580 felodipine Drugs 0.000 claims description 5
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 claims description 5
- 229960004294 lercanidipine Drugs 0.000 claims description 5
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 claims description 5
- 229960003963 manidipine Drugs 0.000 claims description 5
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims description 5
- 229960001783 nicardipine Drugs 0.000 claims description 5
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 5
- 229960001597 nifedipine Drugs 0.000 claims description 5
- 229950010800 niguldipine Drugs 0.000 claims description 5
- 229960005366 nilvadipine Drugs 0.000 claims description 5
- 229960000715 nimodipine Drugs 0.000 claims description 5
- 229960000227 nisoldipine Drugs 0.000 claims description 5
- 229960005425 nitrendipine Drugs 0.000 claims description 5
- 229960002992 barnidipine Drugs 0.000 claims description 4
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 claims description 4
- 102000015427 Angiotensins Human genes 0.000 claims description 3
- 108010064733 Angiotensins Proteins 0.000 claims description 3
- 229940044551 receptor antagonist Drugs 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 3
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims description 2
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 4
- 108090001069 Chymopapain Proteins 0.000 claims 3
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000008569 process Effects 0.000 description 22
- 241000282412 Homo Species 0.000 description 21
- 241000124008 Mammalia Species 0.000 description 21
- 239000005480 Olmesartan Substances 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 229960005117 olmesartan Drugs 0.000 description 21
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 21
- 125000000217 alkyl group Chemical group 0.000 description 17
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 description 12
- 230000006820 DNA synthesis Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 description 12
- 230000036772 blood pressure Effects 0.000 description 12
- 229960001199 olmesartan medoxomil Drugs 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000002253 acid Substances 0.000 description 7
- 230000003276 anti-hypertensive effect Effects 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 101100222276 Drosophila melanogaster cuff gene Proteins 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000007634 remodeling Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 238000011260 co-administration Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000003966 vascular damage Effects 0.000 description 4
- 102000005862 Angiotensin II Human genes 0.000 description 3
- 101800000733 Angiotensin-2 Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 229950006323 angiotensin ii Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940000425 combination drug Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 125000005633 phthalidyl group Chemical group 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000036454 renin-angiotensin system Effects 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical class CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 101710095339 Apolipoprotein E Proteins 0.000 description 2
- 102100029470 Apolipoprotein E Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical class C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 150000001483 arginine derivatives Chemical class 0.000 description 2
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 2
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical class C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910052792 caesium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001868 cobalt Chemical class 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- JAUGGEIKQIHSMF-UHFFFAOYSA-N dialuminum;dimagnesium;dioxido(oxo)silane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O.[O-][Si]([O-])=O JAUGGEIKQIHSMF-UHFFFAOYSA-N 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 150000005332 diethylamines Chemical class 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 150000002301 glucosamine derivatives Chemical class 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002332 glycine derivatives Chemical class 0.000 description 2
- 150000002357 guanidines Chemical class 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000002505 iron Chemical class 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 150000002780 morpholines Chemical class 0.000 description 2
- 150000002815 nickel Chemical class 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical class CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- TZNOWAJJWCGILX-BTJKTKAUSA-N (z)-but-2-enedioic acid;3-o-ethyl 5-o-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound OC(=O)\C=C/C(O)=O.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl TZNOWAJJWCGILX-BTJKTKAUSA-N 0.000 description 1
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- ZKFQEACEUNWPMT-MUUNZHRXSA-N 3-o-(1-benzhydrylazetidin-3-yl) 5-o-propan-2-yl (4r)-2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound C1([C@H]2C(=C(N)NC(C)=C2C(=O)OC(C)C)C(=O)OC2CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=CC([N+]([O-])=O)=C1 ZKFQEACEUNWPMT-MUUNZHRXSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 229940095602 acidifiers Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 229960004005 amlodipine besylate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 235000012215 calcium aluminium silicate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OKLAEQBUDFSNDL-UHFFFAOYSA-N calcium;1,4-dihydropyridine Chemical compound [Ca].C1C=CNC=C1 OKLAEQBUDFSNDL-UHFFFAOYSA-N 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000005201 cycloalkylcarbonyloxy group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940127292 dihydropyridine calcium channel blocker Drugs 0.000 description 1
- 239000002866 dihydropyridine calcium channel blocker Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000006351 ethylthiomethyl group Chemical group [H]C([H])([H])C([H])([H])SC([H])([H])* 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000008011 inorganic excipient Substances 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000001452 natriuretic effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000008012 organic excipient Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 125000005767 propoxymethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])[#8]C([H])([H])* 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000001959 sucrose esters of fatty acids Substances 0.000 description 1
- 235000010965 sucrose esters of fatty acids Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 210000004231 tunica media Anatomy 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Description
x 3 . ®
SPECIFICATION
A medicament for the prophylaxis and treatment of arteriosclerosis and hypertension [Technical field]
The present invention relates to a medicament for the prophylaxis and/or treatment of arteriosclerosis. In addition, the present invention relates to a medicament for the prophylaxis and/or medical treatment of diseases such as hypertension, heart diseases (angina pectoris, myocardial infarction, arrhythmia (including sudden death), cardiac failure or cardiac hypertrophy), renal diseases (diabetic nephropathy, glomerulonephritis or nephrosclerosis) or cerebrovascular diseases (cerebral infarction or cerebral hemorrhage). [Background art]
Currently, calcium channel blockers and inhibitors of the renin-angiotensin system are widely used clinically for the prophylaxis and treatment of hypertension. Various types of calcium channel blockers are used, and among them 1,4-dihydropyridine derivatives such as amlodipine, benidipine, nitrendipine, manidipine, nicardipine, nifedipine, nisoldipine, cilnidipine, lercanidipine, niguldipine, nimodipine, aranidipine, efonidipine, barnidipine, felodipine, nilvadipine, azelnidipine and the like are long- lasting calcium channel blockers and are widely used clinically as first-choice antihypertensive agents. Furthermore, as inhibitors of the renin-angiotensin system, clinical use of angiotensin II receptor antagonists is growing larger and larger since, first, angiotensin II receptor antagonists lack side effects such as cough, which has been a cause of troubles elicited by angiotensin converting enzyme (ACE) inhibitors, and second, they exert protective effects on the cardiovascular and renal systems. However,
S:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT) Eng. Trans. of spec./TSA/08.07.05
" « @® 2 . @ the blood pressure of patients with hypertension cannot be fully controlled by only one kind of these drugs in many cases.
Since calcium channel blockers exert natriuretic action in addition to vasodilative action, they are also effective against hypertension caused by retention of fluid (renin- independent hypertension). On the other hand, angiotensin II receptor antagonists are particularly effective against renin-dependent hypertension, and in addition, they exert excellent protective activities in several organs. Therefore stable and significant antihypertensive effects are expected by combined administration of a calcium channel blocker and an angiotensin II receptor antagonist, no matter what the cause of hypertension.
Many combination drugs comprising a calcium channel blocker and an angiotensin
IT receptor antagonist have been proposed (for example, International Publication
Number 01/15674 Official Gazette, International Publication Number 01/78699 Official
Gazette, International Publication Number 02/43807 Official Gazette, International
Publication Number 01/76632 Official Gazette, International Publication Number 01/74390 Official Gazette, Japanese Patent Publication (Kohyo) Number 2002-524408,
International Publication Number 92/10097 Official Gazette, Japanese Patent
Publication (Kokoku) Number Hei 7-035372, United Kingdom Patent Application
Publication Number 2268743 Specification, Japanese Patent Publication (Kokai)
Number Hei 6-56789, Japanese Patent Publication (Kokai) Number Hei 5-155867,
United States Patent Application Publication Number 2001/0004640 Specification, USP 6204281 Specification, Japanese Patent Number 3057471, Japanese Patent Number 2930252, Japanese Patent Publication (Kohyo) Number 2002-507213, Japanese Patent
Publication (Kohyo) Number 2001-513498, Japanese Patent Publication (Kohyo) $:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCTVEng. Trans. of spec./TSA/08.07.05
PCT/JP2004/000861 @¢: Number 2000-508632, Japanese Patent Publication (Kokoku) Number Hei 7-91299,
Japanese Patent Publication (Kokoku) Number Hei 7-14939, Japanese Patent
Publication (Kokai) Number Hei 6-65207, Japanese Patent Publication (Kokai)
Number Hei 5-213894, Japanese Patent Publication (Kohyo) Number 2002-518417,
Japanese Patent Publication (Kohyo) Number 2002-506010, and Japanese Patent
Publication (Kohyo) Number 2001-522872), and it is disclosed that optimum antihypertensive effects are achieved by combined administration of a specific calcium channel blocker and a specific angiotensin II receptor antagonist in some of these publications described above. However, the effects of combined administration of a specific angiotensin II receptor antagonist and a specific calcium channel blocker of the present invention are not known.
On the other hand, characteristics of pathological changes at the early stages of arteriosclerosis are abnormal thickening of the middle arteries or large arteries, and the pathological changes at the early stage of arteriosclerosis are characterized by injury of the endothelium, migration of vascular smooth muscle cells (VSMC) to the tunica intima of the blood vessels, proliferation of vascular smooth muscle cells, accumulation of lipids within the cells (foam cells), and the like. In addition, under hypertensive conditions, which are associated with progression of arteriosclerosis, it is known that vascular cytoarchitecture is changed by responding to various loading factors to the vessels and remodeling of the vessels occurs. Remodeling of the vessels indicates structural changes in the vessels caused by hemodynamic changes such as changes of blood flow and tension of blood vessel walls. In addition to substances such as growth factors and cytokines, vasoactive substances are suggested to contribute to the development processes. For example, it is known that angiotensin II :
AMENDED SHEET
4 PCT/JP2004/000861
Lo ~ ( 2 facilitates proliferation of vascular smooth muscle cells (Medical Clinics of Japan,
Vol. 21, 1924, 1995), and also facilitates remodeling of vessels (Journal of Clinical and Experimental Medicine IGAKU NO AYUMI), Vol. 193, 361, 2000).
However, detailed mechanisms of progression of arteriosclerosis from pathogenesis to advanced disease are not sufficiently clarified. In addition, detailed mechanisms of vascular remodeling are also unknown. Although there are some reports describing relationships between angiotensin II receptor antagonists and vascular remodeling (Circulation, 104, 2716, 2001), the effects of calcium channel blockers on pathological changes in arteriosclerosis and vascular damage as well as their mechanisms are little known. Furthermore, the prophylactic and therapeutic effects of combined administration of a calcium channel blocker and an angiotensin II receptor antagonist against arteriosclerosis are little reported, if at all. Particularly, the effects of calcium channel blockers on the renin-angiotensin system and the synergistic effects of a calcium channel blocker and an angiotensin II receptor antagonist are little known, despite the fact that they are important subjects in : therapeutic aspects of arteriosclerosis.
Furthermore, since percutaneous coronary intervention (PCI) including percutaneous transluminal coronary angioplasty (PTCA) and stent implantation have low invasiveness, they occupy the central position in current therapeutic strategies against ischemic heart diseases. However, restenosis appearing within several months after surgery in 30-45 % patients undergoing these surgical procedures is a major problem. As for the mechanisms of restenosis following PCI, decreases in the : diameters of whole vessels in the late period after PCI (that is, remodeling) are considered important, in addition to hyperplasia and hypertrophy of neointima caused by proliferation of smooth
AMENDED SHEET v ® 5 ® muscle cells and accumulation of extracellular matrix, which is produced by the smooth muscle cells (Coronary Intervention, Vol. 1, 12; Medical Clinics of J apan, Vol. 21, 1924, 1995). Under these circumstances, development of new medicaments that can effectively prevent restenosis of vessels following PCI is needed. Nevertheless, no medicaments with high efficacy have so far been developed. [Disclosure of the invention]
The subject of the present invention is to provide medicaments for the prevention and/or treatment of arteriosclerosis. More concretely, it is the subject of the present invention to provide medicaments to prevent or to inhibit the proliferation of vascular : smooth muscles and neointima formation in blood vessels. Furthermore, another subject of the present invention is to provide medicaments that effectively inhibit remodeling of vessels and prevent progression of arteriosclerosis as well as restenosis of vessels following PCI.
Furthermore, the other subject of the present invention is to provide medicaments for the prophylaxis or treatment of hypertension or diseases caused by hypertension. More concretely, the subject is to provide medicaments for the prophylaxis and/or medical treatment of hypertension, heart diseases [angina pectoris, myocardial infarction, arrhythmia (including sudden death), cardiac failure or cardiac hypertrophy], renal diseases (diabetic nephropathy, glomerulonephritis or nephrosclerosis) or cerebrovascular diseases (cerebral infarction or cerebral hemorrhage) (particularly medicaments for the prevention or treatment of hypertension).
The present inventors have fastidiously studied the subjects described above, and found that combined administration of a specific calcium channel blocker and a specific $:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCTY Eng. Trans. of spec./TSA/08.07.05
Lj [ 6 ® angiotensin II receptor antagonist potently prevents proliferation of vascular smooth muscle cells as well as neointima formation in blood vessels, and that the inhibitory action of the combined administration of the two kinds of agents was discovered to be synergistic, and also found that the inhibitory action was potently observed at lower doses than their effective doses when they were administered alone. Moreover, the present inventors found that combined administration as described above remarkably prevented vascular remodeling and that the medicament effectively inhibited restenosis following PCL
Furthermore, the present inventors found that combined administration of the specific calcium channel blocker and the specific angiotensin II receptor antagonist described above could achieve excellent antihypertensive action. In addition, the present inventors found that the present medicament is remarkably effective for the prophylaxis and/or treatment of hypertension, heart diseases [angina pectoris, myocardial infarction, arrhythmia (including sudden death), cardiac failure or cardiac hypertrophy], renal diseases (diabetic nephropathy, glomerulonephritis or nephrosclerosis) or cerebrovascular disorders (cerebral infarction or cerebral hemorrhage). Thus the present invention was completed based on these findings described above.
The present invention provides a medicament for the prevention and/or treatment of arteriosclerosis, comprising the following composition: $:/Chemical/Sankyo/FPO402/FP0402s P92776/FP-0402(PCTYEng. Trans. of spec./TSA/08.07.05
@® 7 (A) an angiotensin II receptor antagonist selected from the group consisting of a compound having a general formula (I),
HiC
CH,
J) \ OH
HC a COOH ty)
JS [ \ NH pharmacologically acceptable esters thereof and pharmacologically acceptable salts thereof; and (B) a calcium channel blocker selected from the group consisting of 1,4- dihydropyridine derivatives and pharmacologically acceptable salts thereof as active ingredients.
Furthermore, from another different point of view of the present invention, it provides a medicament for the inhibition of the proliferation of vascular smooth muscle cells comprising the compound (A) and the compound (B) as active ingredients; a medicament for the inhibition of neointima formation in blood vessels comprising the compound (A) and the compound (B) as active ingredients; and a medicament for the inhibition of vascular remodeling comprising the compound (A) and the compound (B) as the active ingredients. These medicaments can be used, for example, as a prophylactic agent for restenosis following percutaneous coronary intervention. From
S:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT) Eng. Trans. of spec./TSA/08.07.05 v @® 8 this point of view, a medicament for the prevention of restenosis following percutaneous coronary intervention comprising the compound (A) and the compound (B) is provided by the present invention.
Furthermore, the present invention provides a medicament for the prevention and/or treatment of hypertension or diseases caused by hypertension comprising the following compounds as active ingredients; (A) an angiotensin II receptor antagonist selected from the group consisting of a compound having the formula (I) described above, pharmacologically acceptable esters thereof and pharmacologically acceptable salts thereof: and (B) a calcium channel blocker selected from the group consisting of 1,4- dihydropyridine derivatives and pharmacologically acceptable salts thereof; and a medicament for the prevention and/or treatment of heart diseases [angina pectoris, myocardial infarction, arrhythmia (including sudden death), cardiac failure, cardiac hypertrophy and the like], renal diseases (diabetic nephropathy, glomerulonephritis, nephrosclerosis and the like), or cerebrovascular disorders (cerebral infarction, cerebral hemorrhage and the like comprising the following compounds as active ingredients; (A) an angiotensin II receptor antagonist selected from the group consisting of a compound having the formula (I) described above, pharmacologically acceptable esters thereof and pharmacologically acceptable salts thereof; and (B) a calcium channel blocker selected from the group consisting of 1,4- dihydropyridine derivatives and pharmacologically acceptable salts thereof.
According to a preferred embodiment of the invention, the medicament described above is provided as a pharmaceutical composition comprising the compound (A) and the compound (B) as active ingredients. This pharmaceutical composition may contain $:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT)/Eng. Trans. of spec./TSA/08.07.05
[ one or more excipients for formulation. According to another preferred embodiment of the invention, a medicament described above to administer the compound (A) and the compound (B) at the same time or separately at certain intervals is provided.
Furthermore, according to a more preferred embodiment of the invention, the medicament described above is provided as a pharmaceutical composition comprising an angiotensin II receptor antagonist and a calcium channel blocker, wherein said angiotensin II receptor antagonist is (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1- hydroxy-1-methylethyl)-2-propyl-1-[[2’-(1H-tetrazol-5-yl)biphenyl-4- ylJmethyl]imidazol-5-carboxylate (hereinafter it is referred to as “olmesartan medoxomil” in some parts of the present specification) and said calcium channel blocker is any one selected from the group of calcium channel blockers comprising (£)- 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylate-3-(1- diphenylmethylazetidin-3-yl)ester 5-isopropylester (hereinafter it is referred to as “azelnidipine” in some parts of the present specification); amlodipine, benidipine, nitrendipine, manidipine, nicardipine, nifedipine, nisoldipine, cilnidipine, lercanidipine, niguldipine, nimodipine, aranidipine, efonidipine, barnidipine, felodipine, and nilvadipine; and the preferred calcium channel blocker is azelnidipine.
From another aspect of the present invention, the present invention provides the use of an angiotensin II receptor antagonist selected from the group consisting of a compound having the formula (I) described above, pharmacologically acceptable esters thereof and pharmacologically acceptable salts thereof to manufacture the medicament described above; and the use of a calcium channel blocker selected from the group consisting of 1,4-dihydropyridine derivatives and pharmacologically acceptable salts thereof to manufacture the medicament described above. $:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT)/Eng. Trans. of spec./TSA/08.07.05
®
Furthermore, the present invention provides methods for the prophylaxis and/or treatment of arteriosclerosis, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the inhibition of the proliferation of vascular smooth muscle cells, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the inhibition of neointima formation of blood vessels, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the inhibition of vascular remodeling, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; and methods for the inhibition of restenosis following percutaneous coronary intervention, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans. Preferably, in the present invention the effective dose of each composition comprising the compound (A) and the compound (B) is around the lowest limit or below the lowest limit of the effective dose of the compound (A) or the compound (B) when administered alone.
Furthermore, the present invention provides methods for the prophylaxis and/or treatment of hypertension or diseases caused by hypertension, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis or treatment of hypertension, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis or treatment of heart diseases, comprising any process of administration of effective doses $:/Chemical/Sankyo/FPO402/FP0402s P92776/FP-0402(PCT)Eng. Trans. of spec. /TSA/08.07.05
' ¢o 11 ® of said compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis or treatment of angina pectoris, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis or treatment of myocardial infarction, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis or treatment of arrhythmia, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis of sudden death, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis or treatment of heart failure, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis or treatment of cardiac hypertrophy, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis or treatment of renal diseases, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis or treatment of diabetic nephropathy, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis or treatment of glomerulonephritis, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis or treatment of nephrosclerosis, comprising any process of administration of effective doses of said $:/Chemical/Sankyo/FPO402/FP0402s P92776/FP-0402(PCTY Eng.
Trans. of spec./TSA/08.07.05
® compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis or treatment of cerebrovascular diseases, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; methods for the prophylaxis or treatment of cerebral infarction, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans; and/or methods for the prophylaxis or treatment of cerebral haemorrhage, comprising any process of administration of effective doses of said compound (A) and said compound (B) to mammals including humans. [Brief description of the drawings]
Fig. 1 indicates the results for the inhibition of DNA synthesis in vascular smooth muscle cells by a calcium channel blocker, azelnidipine, at a dose range of 0.1 to 1.0 mg/kg/day.
Fig. 2 shows the results for inhibition of neointima formation in blood vessels by a calcium channel blocker, azelnidipine, at a dose range of 0.1 to 1.0 mg/kg/day.
Fig. 3 represents the results for inhibition of DNA synthesis in vascular smooth muscle cells by an angiotensin II receptor antagonist, olmesartan, at a dose range of 0.5 to 3.0 mg/kg/day.
Fig. 4 indicates the results for inhibition of neointima formation in blood vessels by an angiotensin II receptor antagonist, olmesartan, at a dose range of 0.5 to 3.0 mg/kg/day.
Fig. 5 shows the results for inhibition of DNA synthesis in vascular smooth muscle cells by simultaneous administration of azelnidipine and olmesartan at doses of 0.1 $:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCTYEng. Trans. of spec./TSA/08.07.05 mg/kg/day and 0.5 mg/kg/day, respectively (at which doses they did not elicit any significant effects by each of these drugs alone).
Fig. 6 represents the results for inhibition of neointima formation in blood vessels by simultaneous administration of azelnidipine and olmesartan at doses of 0.1 mg/kg/day and 0.5 mg/kg/day, respectively (at which doses they did not elicit any significant effects by each of these drugs alone).
Fig. 7 indicates the results for inhibition of potentiation of DNA synthesis in cultured rat vascular smooth muscle cells following stimulation of angiotensin II receptors by azelnidipine in a concentration-dependent manner.
Fig. 8 shows the results for significant inhibition of DNA synthesis in cultured vascular smooth muscle cells by co-administration of azelnidipine and olmesartan at low concentrations, at which concentrations they did not elicit any significant effects by each of these drugs alone. [Best mode for carrying out the invention]
The medicaments of the present invention are characterized by containing (A) an angiotensin II receptor antagonist selected from the group consisting of a compound having the formula (I) described above, pharmacologically acceptable esters thereof and pharmacologically acceptable salts thereof; and (B) a calcium channel blocker selected from the group consisting of 1,4-dihydropyridine derivatives and pharmacologically acceptable salts thereof as active ingredients.
The compound having the formula (I) described above, [4-(1-hydroxy-1- methylethyl)-2-propyl-1-[[2’-(1H-tetrazol-5-yl)biphenyl-4-yl Jmethyl Jimidazol-5- carboxylic acid] is a known compound, and for example, it is easily obtained by $:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCTYEng. Trans. of spec./TSA/08.07.05
® methods disclosed in Japanese Patent Publication (Kokai) Number Hei 5-78328 (USP 5,616,599 Specification), and the like. The pharmacologically acceptable salts of the compound having the formula (I) described above are not specifically restricted and these salts can be selected by a person with an ordinary skill in the art. As pharmacologically acceptable salts of the compound having the formula (I) described above, such salts are, for example, an alkaline metal salt such as sodium salt, potassium salt or lithium salt; an alkaline earth metal salt such as calcium salt or magnesium salt; a metal salt such as aluminium salt, iron salt, zinc salt, copper salt, nickel salt or cobalt salt; an amine salt such as an ammonium salt, t-octylamine salt, dibenzylamine salt, morpholine salt, glucosamine salt, phenylglycine alkyl ester salt, ethylenediamine salt,
N-methylglucamine salt, guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, N,N’-dibenzylethylenediamine salt, chloroprocaine salt, procaine salt, diethanolamine salt, N-benzyl-phenethylamine salt, piperazine salt, tetramethylammonium salt or tris(hydroxymethyl)aminomethane salt, but not restricted to these salts. Preferably alkaline metal salts can be used, and particularly preferably the sodium salt can be used.
The pharmacologically acceptable esters of the compound having the formula OD comprise the compound having the formula (I) of which a carboxyl moiety is esterified.
The pharmacologically acceptable esters are not particularly restricted, and can be selected by a person with an ordinary skill in the art. In the case of said esters, it is preferable that such esters can be cleaved by a biological process such as hydrolysis in vivo. The group constituting the said esters (the group shown as R when the esters thereof are expressed as —COOR) can be, for example, a C;-C, alkoxy C;-Cs alkyl group such as methoxyethyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, 1-
S:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT)/Eng. Trans. of spec./TSA/08.07.05
® (isopropoxy)ethyl, 2-methoxyethyl, 2-ethoxyethyl, 1,1-dimethyl-1-methoxymethyl, ethoxymethyl, propoxymethyl, isopropoxymethyl, butoxymethyl or t-butoxymethyl; a
C,-C4 alkoxylated C;-C, alkoxy C;-C, alkyl group such as 2-methoxyethoxymethyl; a
Ce-Cio aryloxy C;-C4 alkyl group such as phenoxymethyl; a halogenated C;-Cs alkoxy
C,-C, alkyl group such as 2,2,2-trichloroethoxymethyl or bis(2-chloroethoxy)methyl; a
C1-C4 alkoxycarbonyl Ci-C, alkyl group such as methoxycarbonylmethyl; a cyano C-
Cs alkyl group such as cyanomethyl or 2-cyanoethyl; a C;-C; alkylthiomethyl group such as methylthiomethyl or ethylthiomethyl; a C4-Co arylthiomethyl group such as phenylthiomethyl or naphthylthiomethyl; a C,-C, alkylsulfonyl C,-C4 lower alkyl group, which may be optionally substituted with a halogen atom(s) such as 2- methanesulfonylethyl or 2-trifluoromethanesulfonylethyl; a Cs-Cyo arylsulfonyl C;-C, alkyl group such as 2-benzenesulfonylethyl or 2-toluenesulfonylethyl; a C,-C; aliphatic acyloxy C,-C; alkyl group such as formyloxymethyl, acetoxymethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl, valeryloxymethyl, isovaleryloxymethyl, hexanoyloxymethyl, 1-formyloxyethyl, 1-acetoxyethyl, 1- propionyloxyethyl, 1-butyryloxyethyl, 1-pivaloyloxyethyl, 1-valeryloxyethyl, 1- isovaleryloxyethyl, 1-hexanoyloxyethyl, 2-formyloxyethyl, 2-acetoxyethyl, 2- propionyloxyethyl, 2-butyryloxyethyl, 2-pivaloyloxyethyl, 2-valeryloxyethyl, 2- isovaleryloxyethyl, 2-hexanoyloxyethyl, 1-formyloxypropyl, 1-acetoxypropyl, 1- propionyloxypropyl, 1-butyryloxypropyl, 1-pivaloyloxypropyl, 1-valeryloxypropyl, 1- isovaleryloxypropyl, 1-hexanoyloxypropyl, 1-acetoxybutyl, 1-propionyloxybutyl, 1- butyryloxybutyl, 1-pivaloyloxybutyl, 1-acetoxypentyl, 1-propionyloxypentyl, 1- butyryloxypentyl, 1-pivaloyloxypentyl or 1-pivaloyloxyhexyl; a Cs-Cg cycloalkylcarbonyloxy C:-C, alkyl group such as cyclopentylcarbonyloxymethyl,
S:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCTY/Eng,. Trans. of spec./TSA/08.07.05
@ cyclohexylcarbonyloxymethyl, 1-cyclopentylcarbonyloxyethyl, 1- cyclohexylcarbonyloxyethyl, 1-cyclopentylcarbonyloxypropyl, 1- cyclohexylcarbonyloxypropyl, 1-cyclopentylcarbonyloxybutyl or 1- cyclohexylcarbonyloxybutyl; a Ce-Cy arylcarbonyloxy C;-Cy alkyl group such as benzoyloxymethyl; a C;-Cg alkoxycarbonyloxy C,-C4 alkyl group such as methoxycarbonyloxymethyl, 1-(methoxycarbonyloxy)ethyl, 1- (methoxycarbonyloxy)propyl, 1-(methoxycarbonyloxy)butyl, 1- (methoxycarbonyloxy)pentyl, 1-(methoxycarbonyloxy)hexyl, ethoxycarbonyloxymethyl, 1-(ethoxycarbonyloxy)ethyl, 1-(ethoxycarbonyloxy)propyl, 1-(ethoxycarbonyloxy)butyl, 1-(ethoxycarbonyloxy)pentyl, 1- (ethoxycarbonyloxy)hexyl, propoxycarbonyloxymethyl, 1-(propoxycarbonyloxy)ethyl, 1-(propoxycarbonyloxy)propyl, 1-(propoxycarbonyloxy)butyl, isopropoxycarbonyloxymethyl, 1-(isopropoxycarbonyloxy)ethyl, 1- (isopropoxycarbonyloxy)butyl, butoxycarbonyloxymethyl, 1-(butoxycarbonyloxy)ethyl, 1-(butoxycarbonyloxy)propyl, 1-(butoxycarbonyloxy)butyl, isobutoxycarbonyloxymethyl, 1-(isobutoxycarbonyloxy)ethyl, 1- (isobutoxycarbonyloxy)propyl, 1-(isobutoxycarbonyloxy)butyl, t- butoxycarbonyloxymethyl, 1-(t-butoxycarbonyloxy)ethyl, pentyloxycarbonyloxymethyl, 1-(pentyloxycarbonyloxy)ethyl, 1- (pentyloxycarbonyloxy)propyl, hexyloxycarbonyloxymethyl, 1- (hexyloxycarbonyloxy)ethyl or 1-(hexyloxycarbonyloxy)propyl; a Cs-Cg cycloalkyloxycarbonyloxy C;-Cs alkyl group such as cyclopentyloxycarbonyloxymethyl, 1-(cyclopentyloxycarbonyloxy)ethyl, 1- (cyclopentyloxycarbonyloxy)propyl, 1-(cyclopentyloxycarbonyloxy)butyl, $:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCTYEng.
Trans. of spec /TSA/08.07.05
® cyclohexyloxycarbonyloxymethyl, 1-(cyclohexyloxycarbonyloxy)ethyl, 1- (cyclohexyloxycarbonyloxy)propyl or 1-(cyclohexyloxycarbonyloxy)butyl; a [5-(C,-Cs alkyl)-2-0x0-1,3-dioxolen-4-ylJmethyl group such as (5-methyl-2-oxo-1,3-dioxolen-4- yDmethyl, (5-ethyl-2-oxo-1,3-dioxolen-4-yl)methyl, (5-propyl-2-oxo-1,3-dioxolen-4- yDmethyl, (5-isopropyl-2-oxo-1,3-dioxolen-4-yl)methyl or (5-butyl-2-oxo-1,3- dioxolen-4-yl)methy; a [5-(phenyl, which may be optionally substituted with a C;-Cs alkyl, C;-C4 alkoxy or halogen atom(s))-2-oxo-1,3-dioxolen-4-ylJmethyl group such as (5-phenyl-2-oxo-1,3-dioxolen-4-yl)methyl, [5-(4-methylphenyl)-2-oxo-1,3-dioxolen-4- ylJmethyl, [5-(4-methoxyphenyl)-2-0xo-1,3-dioxolen-4-yljmethyl, [5-(4-fluorophenyl)- 2-0x0-1,3-dioxolen-4-ylJmethyl or [5-(4-chlorophenyl)-2-o0xo0-1,3-dioxolen-4- yljmethyl; or a phthalidyl group, which may be optionally substituted with a C;-C, alkyl or C,-C,4 alkoxy group(s), such as phthalidyl, dimethylphthalidyl or dimethoxyphthalidyl, and is preferably a pivaloyloxymethyl group, phthalidyl group or (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl group, and more preferably a (5-methyl-2- 0xo-1,3-dioxolen-4-yl)methyl group.
In the case that the esters of the compound of formula (I) described above form pharmacologically acceptable salts, the pharmacologically acceptable salts can be selected by a person with an ordinary skill in the art, and are not particularly restricted.
Such salts can be, for example, a hydrohalogenic acid salt such as a hydrofluoride, hydrochloride, hydrobromide or hydroiodide; a nitrate; a perchlorate; a sulfate; a phosphate; a C,-C, alkanesulfonic acid salt, which may be optionally substituted with a halogen atom(s) such as a methanesulfonate, trifluoromethanesulfonate or ethanesulfonate; a C¢-C) arylsulfonic acid salt, which may be optionally substituted with a C;-C, alkyl group(s), such as a benzenesulfonate or p-toluenesulfonate; a Ci-Cs
S:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT) Eng. Trans. of spec./TSA/08.07.05
. @® 18 @ aliphatic acid salt such as an acetate, malate, fumarate, succinate, citrate, tartrate, oxalate or maleate; or an amino acid salt such as a glycine salt, lysine salt, arginine salt, ornithine salt, glutamic acid salt or aspartic acid salt, and is preferably a hydrochloride, nitrate, sulfate or phosphate, and is particularly preferably a hydrochloride.
The angiotensin II receptor antagonist, which is used as the compound (A), is preferably the compound having the formula (I) described above or a pharmacologically acceptable ester thereof, more preferably a pharmacologically acceptable ester of said compound having the formula (I), and further more preferably a pivaloyloxymethyl ester, phthalidyl ester or (5-methyl-2-0x0-1,3-dioxolen-4-yl)methyl ester of the compound having the formula (I). Most preferably, (5-methyl-2-0x0-1,3-dioxolen-4- yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2’-(1H-tetrazol-5-yl)biphenyl-4- ylJmethyl]imidazol-5-carboxylate can be used.
As the compound selected from the group consisting of a compound having the formula (I) described above, pharmacologically acceptable esters thereof and pharmacologically acceptable salts thereof, their hydrates or solvates can also be used.
In the case that the pharmacologically acceptable esters of the compound having the formula (I) are used, some esterified compounds may have one or more asymmetric carbons, but optical isomers purified based on the said asymmetric carbons or stereoisomers such as diastereoisomers or any mixtures of these stereoisomers or racemates can also be used as the compound (A).
A calcium channel blocker including 1,4-dihydropyridine derivatives, which is used as the compound (B), is a calcium channel blocker characterized by having the 1,4- dihydropyridine moiety or chemically equivalent structural moiety to the 1,4- dihydropyridine moiety in the molecule. Many medicaments are proposed as calcium $:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCTYEng, Trans. of spec. /TSA/08.07.05
. CJ 19 @® channel blockers including the 1,4-dihydropyridine derivatives and are actually used clinically, and a person with an ordinary skill in the art can select any suitable compounds exerting the effects of the present invention. As 1,4-dihydropyridine calcium channel blockers, for example, azelnidipine, amlodipine, benidipine, nitrendipine, manidipine, nicardipine, nifedipine, nisoldipine, cilnidipine, lercanidipine, niguldipine, nimodipine, aranidipine, efonidipine, barnidipine, felodipine, or nilvadipine can be used, but the scope of the present invention should not be limited to these calcium channel blockers exemplified. In addition, azelnidipine can be easily manufactured according to the methods disclosed in Japanese Patent Publication (Kokai) Number Sho 63-253082 (USP 4,772,596 Specification) and the like.
Furthermore, amlodipine can be easily manufactured according to the methods disclosed in USP 4,572,909 Specification or USP 4,879,303 Specification.
Since the pharmacologically acceptable salts of 1,4-dihydropyridine derivatives are not specifically restricted, any salts thereof can be selected by a person with an ordinary skill in the art. The pharmacologically acceptable salts can be acid addition salts or base addition salts. These salts can be, for example, an alkaline metal salt such as a sodium salt, potassium salt or lithium salt; an alkaline earth metal salt such as a calcium salt or magnesium salt; a metal salt such as an aluminum salt, iron salt, zinc salt, copper salt, nickel salt or cobalt salt; or a base addition salt, for example, an amine salt such as an ammonium salt, t-octylamine salt, dibenzylamine salt, morpholine salt, glucosamine salt, phenylglycine alkyl ester salt, ethylenediamine salt, N-methylglucamine salt, guanidine salt, diethylamine salt, triethylamine salt, dicyclohexylamine salt, N,N’- dibenzylethylenediamine salt, chloroprocaine salt, procaine salt, diethanolamine salt, N- benzylphenethylamine salt, piperazine salt, tetramethylammonium salt or
S:/Chemical/Sankyo/FP0O402/FP0402s P92776/FP-0402(PCT)/Eng, Trans. of spec./TSA/08.07.05
@ tris(hydroxymethyl)aminomethane salt; or an acid addition salt, for example, a hydrohalide such as a hydrofluoride, hydrochloride, hydrobromide or hydroiodide; a nitrate; a perchlorate; a sulfate; a phosphate; a C;-Cy alkanesulfonate, which may be optionally substituted with a halogen atom(s) such as a methanesulfonate, trifluoromethanesulfonate or ethanesulfonate; a C4-Cg arylsulfonate, which may be optionally substituted with a C,-C, alkyl group(s) such as a benzenesulfonate or p- toluenesulfonate; a C,-Cs aliphatic acid salt such as an acetate, malate, fumarate, succinate, citrate, tartrate, oxalate or maleate; or an amino acid salt such as a glycine salt, lysine salt, arginine salt, ornithine salt, glutamic acid salt or aspartic acid salt, but the scope of the present invention should not be restricted to these salts described above.
As a calcium channel blocker including 1,4-dihydropyridine derivatives, hydrates or solvates of the compounds described above and pharmacologically acceptable salts thereof can be used. In addition, some calcium channel blockers including 1,4- dihydropyridine derivatives contain one or more asymmetric carbons in their molecules.
In these cases, optical isomers purified based on the asymmetric carbons or stereoisomers such as diastereoisomers, or any mixtures of stereoisomers, or racemates can also be used as the compound (B). As the compound (B), (%)-2-amino-1,4-dihydro- 6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin- 3-yl) ester S5-isopropyl ester, (R)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5- pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl) ester 5 -isopropyl ester, amlodipine besylate, or amlodipine maleate is preferred.
As concretely shown in the Test Examples of the present specification, the medicament of the present invention consisting of the compound (A) and the compound (B) works synergistically and inhibits neointima formation of blood vessels and
S:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCTY Eng. Trans. of spec./TSA/08.07.05
} C 21 ® proliferation of vascular smooth muscle cells and, as a result, inhibits vascular remodeling. Based on the actions described above, the medicaments of the present invention can be used for the prophylaxis of restenosis following percutaneous coronary intervention in addition to the prophylaxis and/or treatment of arteriosclerosis.
The medicament of the present invention is characterized by exerting excellent inhibitory effects on neointima formation of blood vessels and proliferation of vascular smooth muscle cells due to combined administration of the compound (A) and the compound (B) at their lowest limit doses or lower than their lowest limit doses of each composition administered alone. Particularly, it is preferable to co-administer the compound (A) and the compound (B) at low doses at which no effects are elicited on administration of each composition alone.
As concretely shown in Test Examples of the present specification, the medicament of the present invention lowers blood pressure more effectively by synergistic action of the compound (A) and the compound (B). Based on these actions described above, the medicament of the present invention can be used for the prophylaxis and/or treatment of hypertension, heart diseases (angina pectoris, myocardial infarction, arrhythmia (including sudden death), cardiac failure, cardiac hypertrophy and the like), renal diseases (diabetic nephropathy, glomerulonephritis, nephrosclerosis and the like) or cerebrovascular disorders (cerebral infarction, cerebral hemorrhage and the like), and preferably for the treatment. The medicament of the present invention comprising an angiotensin II receptor antagonist and a calcium channel blocker exerts more excellent effects by combined administration of an angiotensin II receptor antagonist and a calcium channel blocker than either one of these agents administered alone.
The medicament of the present invention may be prepared as a pharmaceutical
S:/Chemical/Sankyo/FPO402/FP0402s P92776/FP-0402(PCT)/Eng. Trans. of spec./TSA/08.07.05
} ® 22 @ composition (so-called as a mode of “combination drug”) comprising the compound (A) and the compound (B) as the active ingredients. For example, each active ingredient may be mixed together and may be prepared as a physically single formulation. In addition, the compound (A) and the compound (B) may be prepared separately as an independent formulation and can be provided as a medicament containing a combination of each mode of formulation. The latter medicament can be used as a medicament to administer the compound (A) and the compound (B) at the same time or separately at certain intervals.
Administration of the compound (A) and the compound (B) “at the same time” described in the present specification includes administration of the compound (A) and the compound (B) roughly at the same time and not just restricted to exactly the same time. There is no restriction of the dosage form for administration at the same time; for example, it is included that either one of the compositions is orally administered and the other composition is non-orally administered. Nevertheless, it is favourable to prepare the invention as a single pharmaceutical composition and to take the both compositions simultaneously.
Independent administration of the compound (A) and the compound (B) “at certain intervals” described in the present specification means that the compound (A) and the compound (B) described in the present invention are to be taken independently at different times. The mode of administration for separate administration at certain intervals has no restriction. For instance, it includes that first an angiotensin II receptor antagonist is administered, and then after a certain interval, a calcium channel blocker is administered, or first a calcium channel blocker is administered, and then after a certain $:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT)Eng. Trans. of spec./TSA/08.07.05
. (J 23 @ interval, an angiotensin II receptor antagonist is administered, but the dosage form has no restriction.
The present medicament is manufactured by previously known methods in a suitable dosage form, such as tablets, capsules, granules, powders or syrups for oral administration, or injections or suppositories for parenteral administration, by using pharmacologically acceptable and suitable additive agents such as excipients, lubricants, binders, disintegrants, demulsifiers, stabilizers, flavours, diluents, and the like, if necessary, in addition to the compound (A) and the compound (B), which are the active ingredients, and can be administered. Since the compound (A) and the compound (B) containing in the medicament of the present invention are compounds to be orally administered in general, the medicament of the present invention is favourable to be orally administered.
As "excipients", for instance, organic excipients including sugar derivatives such as lactose, sucrose, glucose, mannitol or sorbitol; starch derivatives such as corn starch, potato starch, a-starch or dextrin; cellulose derivatives such as crystalline cellulose; gum arabic; dextran; or pullulan; and inorganic excipients including silicate derivatives such as light anhydrous silicic acid, synthetic aluminium silicate, calcium silicate or magnesium aluminometasilicate; phosphates such as calcium hydrogenphosphate; carbonates such as calcium carbonate; or sulfates such as calcium sulfate can be listed.
As "lubricants", for instance, stearic acid; metal salts of stearic acid such as calcium stearate and magnesium stearate; talc; colloidal silica; waxes such as beeswax and spermaceti; boric acid; adipic acid; sulfates such as sodium sulfate; glycol; fumaric acid; sodium benzoate; DL-leucine; laurylsulfates such as sodium lauryl sulfate or $:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT)Eng. Trans. of spec /TSA/08.07.05
} ® 24 ® magnesium lauryl sulfate; silicates such as silicic anhydride and silicic hydrate; or the starch derivatives described above can be listed.
As "binders", for instance, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, macrogol, or similar excipients to those described above can be listed.
As "disintegrants", for instance, cellulose derivatives such as low-substituted hydroxypropylcellulose, carboxymethylcellulose, calcium carboxymethylcellulose or internally crosslinked sodium carboxymethylcellulose; and chemically modified starch/cellulose derivatives such as carboxymethylstarch or sodium carboxymethylstarch can be listed.
As "demulsifiers", for instance, colloidal clay such as bentonite or veegum; metal hydroxides such as magnesium hydroxide or aluminium hydroxide; anionic surfactants such as sodium lauryl sulfate or calcium stearate; cationic surfactants such as benzalkonium chloride; or nonionic surfactants such as polyoxyethylenealkylether, polyoxyethylene sorbitan fatty acid ester or sucrose esters of fatty acids can be listed.
As "stabilizers", for instance, p-hydroxybenzoate esters such as methylparaben or propylparaben; alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol; benzalkonium chloride; phenols such as phenol or cresol; thimerosal; dehydroacetic acid; or sorbic acid can be listed.
As "flavours", for instance, sweeteners such as saccharin sodium or aspartame; acidifiers such as citric acid, malic acid or tartaric acid; or flavours such as menthol, lemon or orange can be listed.
As "diluents", conventionally used diluents, for instance, lactose, mannitol, glucose, sucrose, calcium sulfate, calcium phosphate, hydroxypropylcellulose, microcrystalline
S:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT)V Eng. Trans. of spec./TSA/08.07.05
. (| 25 o cellulose, water, ethanol, polyethyleneglycol, propyleneglycol, glycerol, starch, polyvinylpyrrolidone, magnesium aluminometasilicate or a mixture of these compounds can be listed.
Doses of an angiotensin II receptor antagonist and a calcium channel blocker, which are active ingredients, and their dosing ratio can be selected in a suitable manner depending on various factors such as the drugs’ activities and symptoms, age and body weight of the patients. Although the dosage varies depending on symptoms, age and the like, in the case of oral administration, 0.1 mg (preferably 0.5 mg) as a lower limit and 1000 mg (preferably 500 mg) as an upper limit per one time for a human adult and one to six times per day depending on the symptoms of the patients can be administered, at the same time or separately at certain intervals. In the case of parenteral administration, 0.01 mg (preferably 0.05 mg) as a lower limit and 100 mg (preferably 50 mg) as an upper limit per one time for a human adult and one to six times per day depending on the symptoms of the patients, at the same time or separately at certain intervals, can be administered. For instance, the dosing ratio of the compound (A) and the compound (B) can range from 1:10000 to 10000:1 in weight ratios, preferably it can be in the range of 1:1000 to 1000:1, and more preferably it can be in the range of 1:100 to 100:1.
When the medicament of the present invention is used for the prophylaxis and/or treatment of arteriosclerosis, it is desirable, in general, that the blood concentration of the compound (A) and the compound (B) after administration is properly adjusted so as to be around the lowest limit or below the lowest limit of the compound (A) or the compound (B) when administered alone.
When the medicament of the present invention is used for the prophylaxis and/or treatment of hypertension, the dosage of angiotensin II receptor antagonist can be
S:/Chemical/Sankyo/FPO402/FP0402s P92776/FP-0402(PCT)/Eng. Trans. of spec./TSA/08.07.05
: C 26 @ prescribed at lower doses than the dosage of the angiotensin II receptor antagonist when the angiotensin II receptor antagonist is used alone as a hypotensive agent, which is its original use, and the dosage of the angiotensin II receptor antagonist can be enormously reduced, because excellent antihypertensive action can be achieved by combined administration of an angiotensin IT receptor antagonist with a calcium channel blocker. [Examples]
The present invention will be hereinafter described in more detail by way of the
Examples and Test Examples described below, but the scope of the present invention should not be limited to these examples. In the Test Examples, “olmesartan medoxomil” 1s simply called “olmesartan”.
Test Example 1: Inhibitory effects against arteriosclerosis (A) Materials and Methods (1) Cuff-induced vascular injury model
C57BL/6 mice aged 10 weeks were used. In a part of this study, AT1a receptor gene knock out (AT1aKO) mice were also used. Inflammatory vascular damage was induced in mice by loosely placing a polyethylene tube which was cut longitudinally to open the tube, around the femoral artery of mice. In the damaged artery, the following observations were determined. The usefulness of this model of vascular damage to analyze vascular remodeling has been previously reported (Physiol. Genomics., 2, pp. 13 - 30, 2000; Circulation, 104, pp. 2716 — 2721, 2001; Circulation, 106, pp. 847 - 853, 2002). $:/Chemical/Sankyo/FPO402/FP0402s P92776/FP-0402(PCTY/Eng, Trans. of spec./TSA/08.07.05
} ® 27 ® (2) Neointima formation in the blood vessels and DNA synthesis
A paraffin-embedded section of the damaged artery was prepared 14 days after cuff placement, Elastica van Gieson staining was carried out, and the cross-sectional area of the neointima and tunica media of the blood vessels was determined by image analysis software. For quantification of DNA synthesis, bromodeoxyuridine (BrdU) was injected into the mice 7 days after cuff placement and BrdU index calculated from incorporation into the nuclei of the cells was calculated. 3) Olmesartan, an AT1 receptor blocker, was intraperitoneally injected into wild- type mice by osmotic minipump, and the dose-dependency of olmesartan was investigated as described in (2). Oral administration of azelnidipine to the wild-type mice was started after cuff placement, and dose-dependency of azelnidipine was investigated as described in (2). (4) Both olmesartan and azelnidipine were simultaneously administered to wild- type mice, and the effects of co-administration of olmesartan and azelnidipine were compared with those of administration of either olmesartan or azelnidipine alone as described in (2). Effects of olmesartan and azelnidipine were investigated at effective doses of either olmesartan or azelnidipine alone and at insufficient doses to elicit significant effects by either olmesartan or azelnidipine alone, so as to determine synergistic effects of these two agents. (5) By using cultured rat vascular smooth muscle cells, the effects of co-treatment of olmesartan and azelnidipine on facilitation of DNA synthesis following stimulation by angiotensin II (determined by incorporation of [*H]thymidine) were investigated. (B) Results (1) Inthe cuff-induced vascular damage model of wild-type mice, DNA synthesis of $:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT)/Eng. Trans. of spec /TSA/08.07.05
® vascular smooth muscle cells was increased and neointima formation in the blood vessels was potentiated. These changes were inhibited by azelnidipine in a dose- dependent manner at a dose range of 0.1 to 1.0 mg/kg/day, without any effects on blood pressure (Fig. 1 and Fig. 2). In addition, olmesartan exhibited similar inhibitory effects in a dose-dependent manner at a dose range of 0.5 to 3.0 mg/kg/day, without any effects on blood pressure (Fig. 3 and Fig. 4). When 0.1 mg/kg/day of azelnidipine and 0.5 mg/kg/day of olmesartan (both of these drugs did not elicit any significant effects at these doses) were administered at the same time, the increase in DNA synthesis of vascular smooth muscle cells and potentiation of neointima formation in the blood vessels were significantly suppressed (Fig. 5 and Fig. 6). From these results, it was clearly demonstrated in vivo that co-administration of azelnidipine and olmesartan works synergistically, inhibits proliferation of the vascular smooth muscle cells and improves vascular remodeling. : (2) The synergistic action of azelnidipine and olmesartan described above was investigated in an in vitro study. As shown in Fig. 7, facilitation of DNA synthesis in cultured rat vascular smooth muscle cells following stimulation by angiotensin II was suppressed by administration of azelnidipine in a concentration-dependent manner.
When low doses of azelnidipine and olmesartan insufficient to elicit any effects alone were co-administered, DNA synthesis of cultured rat vascular smooth muscle cells was significantly suppressed (Fig. 8).
Test Example 2: Antihypertensive activity
Surgical operations were carried out in 56 spontaneously hypertensive rats (SHRs,
SPF grade, Breeder: Hoshino Laboratory Animals) aged 20 weeks to implant
S:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT)/Eng. Trans. of spec./TSA/08.07.05
. C 29 : ® transmitters for recording their blood pressures. After recovery from the surgical operations, their blood pressure was monitored starting at 24 weeks of age. 0.5% carboxymethylcellulose sodium (CMC-Na) solution (2 ml/kg) was orally administered for 7 successive days (once daily) by a dosing cannula. The animals were divided into 7 groups (8 rats per group) with homogenous blood pressure in each group based on their blood pressure determined on the 5th and 6th days from initiation of blood pressure monitoring (the constitution of each group is illustrated in Table 1). Then either 0.5%
CMC-Na solution (2 ml/kg: control group) or test drug solution (2 ml/kg) in which the test substance was suspended in 0.5% CMC-Na solution was administered from 25 weeks of age for 14 successive days (once daily) and changes in blood pressure were observed. Changes in the blood pressure of group 6 and group 7 are shown in Table 2. (Values in the tables represent mean + S.D.) Excellent antihypertensive effects were observed in animals in the group co-administered olmesartan plus azelnidipine.
Table 1.
Group 1 Control group (0.5% CMC-Na solution)
Group 2 Olmesartan medoxomil (0.2 mg/kg)
Group 3 Olmesartan medoxomil (1.0 mg/kg)
Group 4 Azelnidipine (2.0 mg/kg)
Group 5 Azelnidipine (5.0 mg/kg)
Group 6 Olmesartan medoxomil (0.2 mg/kg) + azelnidipine (2.0 mg/kg)
Group 7 Olmesartan medoxomil (1.0 mg/kg) + azelnidipine (5.0 mg/kg)
Table 2
S:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT) Eng. Trans. of spec./TSA/08.07.05
@
ComwolGroup [8] 16922238 | 167.0 £206 [17042111 | 17304213
Gomi [s| moss 7 | sess [wasn | sess
Gow? [5] mzena | mses mason [si00
Test Example 3: Antihypertensive Effects
Male apolipoprotein E (ApoE) knock out mice aged 12 weeks were divided into 4 groups (15 mice per group) as following: control group (0.5% carboxymethylcellulose (CMC) solution administered group), olmesartan medoxomil (3 mg/kg) administered group, azelnidipine (3 mg/kg) administered group, and olmesartan medoxomil (3 mg/kg) plus azelnidipine (3 mg/kg) administered group. Either test substance or vehicle (0.5% CMC solution) was orally administered to animals for 24 successive weeks. A high fatty diet (containing 0.15% cholesterol and 15% unsalted butter) was given to all mice in all groups following the start of test agent administration (12 weeks of age). The systolic blood pressure of all mice was measured by a non-preheating type blood pressure monitor (BP MONITOR FOR RATS & MICE, Model MK-2000, Muromachi
Kikai Co., Ltd.) at 21 — 24 hr after drug administration in the 23rd week. The results are shown in Table 3 (values in the table indicate mean + S.E.).
S:/Chemical/Sankyo/FPO402/FPO402s P92776/FP-0402(PCTYEng. Trans. of spec./TSA/08.07.05
} @® 31 @
Table 3
Olmesartan medoxomil and azelnidipine co-
As the results show above, remarkable hypotensive effects (p = 0.0063; Dunnett’s multiple comparison test) were observed in the olmesartan medoxomil and azelnidipine co-administered group, at which doses either agent alone did not elicit any significant effects, and the effects elicited by co-administration of olmesartan medoxomil and azelnidipine were synergistic (p = 0.0065; two-way analysis of variance). (Preparation example)
Tablets (Combination Drug)
Olmesartan medoxomil 10.0 mg
Azelnidipine 10.0 mg
Lactose 278.0 mg
Corn Starch 50.0 mg
Magnesium stearate 20 mg
The powders of above prescription are mixed and tableted with a tableting machine to prepare a tablet comprising 350 mg of the composition. The tablets can be sugar coated, when it is necessary. $:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT)/Eng. Trans. of spec./TSA/08.07.05
. ¢o 32 [Industrial applicability]
The medicament of the present invention is useful as a prophylactic and/or therapeutic agent against arteriosclerosis and hypertension.
S:/Chemical/Sankyo/FP0402/FP0402s P92776/FP-0402(PCT)/Eng. Trans. of spec./TSA/08.07.05
Claims (1)
- PC1/1P2004/000861 CLAIMSI. A substance or composition for use in a method for the prevention and/or treatment of arteriosclerosis comprising: (A) an angiotensin II receptor antagonist selected from the group consisting of a compound having a general formula (I), pharmacologically acceptable esters thereof and pharmacologically acceptable salts thereof, and HaC CH, BS nN coon @ N JTS \ : NH NT (B) a calcium channel blocker sclected from the group consisting of 1,4- dihydropyridine derivatives and pharmacologically acceptable salts thercof as active ingredients, and said method comprising administering said substance or composition.2. A substance or composition for use with (A) an angiotensin II receptor antagonist selected from the group consisting of a compound having a general formula (1), pharmacologically acceptable esters thereof and pharmacologically acceptable salts thereof as defined in Claim 1, in a method for the prevention and/or treatment of arteriosclerosis, said substance or composition comprising (B) a calcium channel blocker selected from the group consisting of 1,4-dihydropyridine derivatives and AMENDED SHEETPCT/IP2004/000861 ® a4 pharmacologically acceptable salts thereof, and said method comprising administering said substance or composition and said angiotensin II receptor antagonist.3. A substance or composition for use with (B) a calcium channel blocker selected from the group consisting of 1,4-dihydropyridine derivatives and pharmacologically acceptable salts thereof in a method for the prevention and/or treatment of arteriosclerosis, said substance or composition comprising (A) an angiotensin 1I receptor antagonist selected from the group consisting of a compound having a general formula (I), pharmacologically acceptable esters thereof and pharmacologically acceptable salts thereof as defined in Claim 1, and said method comprising administering said substance or composition and said calcium channel blocker.4. A substance or composition for usc in a method for the inhibition of proliferation of vascular smooth muscle cells, comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition.5. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the inhibition of proliferation of vascular smooth muscle cells, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound(A).6. A substance or composition for use with compound (B) as defined in Claim 1 in a method for the inhibition of proliferation of vascular smooth muscle cells, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound(B).7. A substance or composition for use in a method for the inhibition of neointima formation of the blood vessels, comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition. AMENDED SHEETPCT/JP2004/000861 ® 3s8. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the inhibition of neointima formation of the blood vessels, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A).9. A substance or composition for use with compound (B) as defined in Claim 1 in a method for the inhibition of neointima formation of the blood vessels, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B).10. A substance or composition for use in a method for the inhibition of vascular remodeling comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition.11. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the inhibition of vascular remodeling, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A).12. A substance or composition for use with compound (B) as defined in Claim 1, in a method the inhibition of vascular remodeling, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B).13. A substance or composition for use in a method for the prevention of restenosis following percutaneous coronary intervention, comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition.14. A substance or composition for use with compound (A) as defined in Claim | in a method for the prevention of restenosis following percutaneous coronary intervention, AMENDED SHEETPCT/JP’2004/000861 ® 36 said substance or composition comprising compound (B) as defined in Claim 1, and said mcthod comprising administering said substance or composition and said compound(A).15. A substance or composition for use with compound (B) as defined in Claim ] in a method for the prevention of restenosis following percutaneous coronary intervention, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound(B).16. A substance or composition for use in a method for the prophylaxis and/or treatment of hypertension or diseases caused by hypertension, comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition, wherein said substance or composition is suitable for administration of compound (A) and compound (B) at the same time.17. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the prophylaxis and/or treatment of hypertension or diseases caused by hypertension, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A), and wherein said compound (A) and said substance or composition can be administered at the same time or separately at certain intervals.18. A substance or composition for usc with compound (B) as defined in Claim 1 in a method for the prophylaxis and/or treatment of hypertension or diseases caused by hypertension, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B), wherein said substance or composition and said compound (B) can be administered at the same time or scparately at certain intervals.19. A substance or composition for use in a method for the prophylaxis and/or treatment of hypertension, comprising compound (A) and compound (B) as defined in AMENDED SHEETPCT/3P2004/000861 ® 37 Claim 1 as active ingredients, and said method comprising administering said substance or composition.20. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the prophylaxis and/or treatment of hypertension, said substance or composition comprising compound (B) as defined in Claim 1 , and said method comprising administering said substance or composition and said compound (A).21. A substance or composition for use with compound (B) as defined in Claim I in a method for the prophylaxis and/or treatment of hypertension, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B).22. A substance or composition for use in a method for the prophylaxis and/or treatment of heart diseases, comprising compound (A) and compound (B) as defined in Claim | as active ingredients, and said method comprising administering said substance or composition.23. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the prophylaxis and/or treatment of heart diseases, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A).24. A substance or composition for use with compound (B) as defined in Claim 1 in a method for the prophylaxis and/or treatment of heart diseases, said substance or composition comprising compound (A) as defined in Claim I, and said method comprising administering said substance or composition and said compound (B).25. A substance or composition for use in a method for the prophylaxis and/or treatment of angina pectoris, comprising compound (A) and compound (B) as defined in Claim | as active ingredients, and said method comprising administering said substance or composition. AMENDED SHEETPCT/1P2004/000861 .26. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the prophylaxis and/or treatment of angina pectoris, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A).27. A substance or composition for use with compound (B) as defined in Claim 1 in a method for the prophylaxis and/or treatment of angina pectoris, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B).28. A substance or composition for use in a method for the prophylaxis and/or treatment of myocardial infarction, comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition.29. A substance or composition for usc with compound (A) as defined in Claim 1 in a method for the prophylaxis and/or treatment of myocardial infarction, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A).30. A substance or composition for use with compound (B) as defined in Claim 1 in a method for the prophylaxis and/or treatment of myocardial infarction, said substance or composition comprising compound (A) as dcfined in Claim 1, and said method comprising administering said substance or composition and said compound (B).31. A substance or composition for use in a method for the prophylaxis and/or treatment of arrhythmia, comprising compound (A) and compound (B) as defined in Claim | as active ingredients, and said method comprising administering said substance or composition.32. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the prophylaxis and/or treatment of arrhythmia, said substance or AMENDED SHEETPCT/IP2004/000861 composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A).33. A substance or composition for use with compound (B) as defined in Claim 1 in a method for the prophylaxis and/or treatment of arrhythmia, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B).34. A substance or composition for use in a method for the prophylaxis of sudden death, comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition.35. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the prophylaxis of sudden death, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A).36. A substance or composition for use with compound (B) as defined in Claim | in a method for the prophylaxis of sudden death, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B).37. A substance or composition for use in a method for the prophylaxis and/or treatment of heart failure, comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition.38. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the prophylaxis and/or treatment of heart failure, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A). AMENDED SHEETPCT/JP2004/000861 ® 439. A substance or composition for use with compound (B) as defined in Claim | in a method for the prophylaxis and/or treatment of heart failure, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B).40. A substance or composition for use in a method for the prophylaxis and/or treatment of cardiac hypertrophy, comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition.41. A substance or composition for use with compound (A) as defined in Claim 1 in amethod for the prophylaxis and/or treatment of cardiac hypertrophy, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A).42. A substance or composition for use with compound (B) as defined in Claim 1 in a method for the prophylaxis and/or treatment of cardiac hypertrophy, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B).43. A substance or composition for use in a method for the prophylaxis and/or treatment of renal discases, comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition.44. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the prophylaxis and/or treatment of renal discases, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A).45. A substance or composition for use with compound (B) as defined in Claim 1, in a method for the prophylaxis and/or treatment of renal diseases, said substance or AMENDED SHEETPCT/JP2004/000861 ® a composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B).46. A substance or composition for use in a method for the prophylaxis and/or treatment of diabetic nephropathy, comprising compound (A) and compound (B) as defined in Claim I as active ingredients, and said method comprising administering said substance or composition.47. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the prophylaxis and/or treatment of diabetic nephropathy, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A).48. A substance or composition for use with compound (B) as defined in Claim 1 in a method for the prophylaxis and/or treatment of diabetic nephropathy, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B).49. A substance or composition for use in a method for the prophylaxis and/or treatment of glomerulonephritis, comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition.50. A substance or composition for use with compound (A) as defined in Claim | in a method for the prophylaxis and/or treatment of glomerulonephritis, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A).S51. A substance or composition for use with compound (B) as defined in Claim 1 in a method for the prophylaxis and/or treatment of glomerulonephritis, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B). AMENDED SHEETPCT/JP2004/000861 ® 252. A substance or composition for use in method for the prophylaxis and/or treatment of nephrosclerosis, comprising compound (A) and compound (B) as defined in Claim | as active ingredients, and said method comprising administering said substance or composition.53. A substance or composition for usc with compound (A) as defined in Claim 1 for the prophylaxis and/or treatment of nephrosclerosis, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A).54. A substance or composition for use with compound (B) as defined in Claim 1 in a method for the prophylaxis and/or treatment of nephrosclerosis, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B).55. A substance or composition for use in a method for the prophylaxis and/or treatment of cerebrovascular diseases, comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition.56. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the prophylaxis and/or treatment of cerebrovascular diseases, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound(A).57. A substance or composition for use with compound (B) as defined in Claim | in a method for the prophylaxis and/or treatment of cerebrovascular diseases, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound(B). AMENDED SHEETPCT/JP2004/000861 ® 558. A substance or composition for use in a method for the prophylaxis and/or treatment of cerebral infarction, comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition.59. A substance or composition for use with compound (A) as defined in Claim | in a method for the prophylaxis and/or treatment of cerebral infarction, said substance or composition comprising compound (B) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (A).60. A substance or composition for use with compound (B) as defined in Claim 1 in a method for the prophylaxis and/or treatment of cerebral infarction, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B).61. A substance or composition for use in a method for the prophylaxis and/or treatment of cerebral hemorrhage, comprising compound (A) and compound (B) as defined in Claim 1 as active ingredients, and said method comprising administering said substance or composition.62. A substance or composition for use with compound (A) as defined in Claim 1 in a method for the prophylaxis and/or treatment of cerebral hemorrhage, said substance or composition comprising compound (B) as defined in Claim 1l,and said method comprising administering said substance or composition and said compound (A).63. A substance or composition for use with compound (B) as defined in Claim 1 in a method for the prophylaxis and/or treatment of cerebral hemorrhage, said substance or composition comprising compound (A) as defined in Claim 1, and said method comprising administering said substance or composition and said compound (B)64. A substance or composition for use in a method of treatment of prevention according to any one Claims 1, 4, 7,10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, AMENDED SHEETPCT/IP2004/000861 ® 44 52, 55, 58 or 61, wherein said substance or composition is a pharmaceutical composition comprising compound (A) and compound (B) as active ingredients.65. A medicament comprising compound (A) and compound (B) as defined in claim 1 as active ingredients.66. A substance or composition for use in a method of treatment or prevention according to any one Claims 2, 3, 5,6, 8,9, 11, 12, 14, 15, 17, 18, 20, 21, 23, 24, 26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 41, 42, 44, 45, 47, 48, 50, 51, 53, 54, 56, 57, 59, 60, 62, or 63, wherein compound (A) and compound (B) are administered at the same time or separately at certain intervals.67. A substance or composition for use in a method of treatment or prevention according to any one Claims 1 to 64, wherein the angiotensin II receptor antagonist is (5-methyl-2-oxo0-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1- [[2’-(1H-tetrazol-5-yl)biphenyl-4-yllmethyl]imidazol-5-carboxylate.68. A substance or composition for use in a method of treatment of prevention according to any one Claims | to 64, wherein the calcium channel blocker is selected from the group consisting of azclnidipine, amlodipine, benidipine, nitrendipine, manidipine, nicardipine, nifedipine, nisoldipine, cilnidipine, lercanidipine, niguldipine, nimodipine, aranidipine, efonidipine, bamidipine, felodipine, and nilvadipine.69. A substance or composition for use in a method of treatment of prevention according to any one Claims 1 to 64, wherein the calcium channel blocker is azelnidipine.70. A substance or composition for use in a method of treatment of prevention according to any onc Claims 1 to 64, wherein the angiotensin II receptor antagonist is (5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylcthyl)-2-propyl-1- [[2’-(1H-tetrazol-5-yl)biphenyl-4-ylJmethyl]-imidazol-S-carboxylate and the calcium channel blocker is azelnidipine. AMENDED SHEETPCT/JP2004/000861 ® 4571. A substance or composition for use in a method of treatment of prevention according to any one Claims 1 to 64, wherein the angiotensin II receptor antagonist is (5-methyl-2-0x0-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1- [[2°-(1H-tetrazol-5-yl)biphenyl-4-yljmcthyl]-imidazol-5-carboxylate and the calcium channel blocker is amlodipine.72. Use of (A) an angiotensin 1 receptor antagonist selected from the group consisting of a compound having a general formula (I), pharmacologically acceptable esters thereof and pharmacologically acceptable salts thereof HaC CH; BS @ N J TS "\ N,N and (B) a calcium channel blocker selected from the group consisting of 1,4- dihydropyridine derivatives and pharmacologically acceptable salts thereof in the manufacture of a medicament for the prevention and/or treatment of arteriosclerosis73. Use of (A) an angiotensin II receptor antagonist selected from the group consisting of a compound having a general formula (I), pharmacologically acceptable esters thereof and pharmacologically acceptable salts thereof as defined in Claim 72, in the manufacture of a preparation for usc with (B) a calcium channel blocker selected AMENDED SHEETPCT/IP2004/000861 ® 4 from the group consisting of 1,4-dihydropyridine derivatives and pharmacologically acceptable salts thereof for the prevention and/or treatment of arteriosclerosis.74. Use of (B) a calcium channel blocker selected from the group consisting of 1,4- dihydropyridine derivatives and pharmacologically acceptable salts thereof in the manufacture of a preparation for use with (A) an angiotensin II receptor antagonist selected from the group consisting of a compound having a general formula (I), pharmacologically acceptable esters thereof and pharmacologically acceptable salts thereof, as defined in Claim 72, for the prevention and/or treatment of arteriosclerosis.75. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the inhibition of proliferation of vascular smooth muscle cells.76. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for usc with compound (B) as defined in Claim 72 for the inhibition of proliferation of vascular smooth muscle cells.71. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A), as defined in Claim 72 for the inhibition of proliferation of vascular smooth muscle cells.78. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the inhibition of neointima formation of the blood vessels.79. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the inhibition of neointima formation of the blood vessels.80. Usc of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the inhibition of neointima formation of the blood vessels. AMENDED SHELTPCT/JP2004/000861 ® 4781. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the inhibition of vascular remodeling.82. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the inhibition of vascular remodeling.83. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the inhibition of vascular remodeling84. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prevention of restenosis following percutaneous coronary intervention.85. Usc of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prevention of restenosis following percutaneous coronary intervention.86. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prevention of restenosis following percutancous coronary intervention.87. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of hypertension or diseases caused by hypertension.88. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of hypertension or diseases caused by hypertension, wherein said medicament and said compound B are administrable at the same time or separately at certain intervals. AMENDED SHEET i PCT/IP2004/00086189. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prophylaxis and/or treatment of hypertension or diseases caused by hypertension, wherein said medicament and said compound A are administrable at the same time or separately at certain intervals.90. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of hypertension.91. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of hypertension.92. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) for the prophylaxis and/or treatment of hypertension.93. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of heart diseases.94. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of heart diseases.9s. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prophylaxis and/or treatment of heart diseases.96. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of angina pectoris.97. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of angina pectoris. AMENDED SHEET i PCT/JP2004/000861 ® 4998. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the for the prophylaxis and/or treatment of angina pectoris.99. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of myocardial infarction.100. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of myocardial infarction.101. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prophylaxis and/or treatment of myocardial infarction.102. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of arrhythmia.103. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of arrhythmia.104. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prophylaxis and/or treatment of arrhythmia.105. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis of sudden death.106. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis of sudden death. AMENDED SHEETPCT/IP2004/000861 o "107. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prophylaxis of sudden death.108. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of heart failure.109. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for usc with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of heart failure.110. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prophylaxis and/or treatment of heart failure.111. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of cardiac hypertrophy.112. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of cardiac hypertrophy.113. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prophylaxis and/or treatment of cardiac hypertrophy.114. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of renal diseases.115. Use of compound (A) as defined in Claim 72 in the manufacturc of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of renal diseases. AMENDED SHEETPCT/JP2004/000861116. Use of compound (B) as dcfined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prophylaxis and/or treatment of renal diseases.117. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of diabetic nephropathy.118. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of diabetic nephropathy.119. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation ; for use with compound (A) as defined in Claim 72 for the prophylaxis and/or treatment of diabetic nephropathy. ! 120. Usc of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of glomerulonephritis.121. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of glomerulonephritis.122. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prophylaxis and/or treatment of glomerulonephritis.123. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of nephrosclerosis. : AMENDED SHEETPCT/JP2004/000861 \ ¢ 52124. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of nephrosclerosis.125. Usc of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prophylaxis and/or treatment of nephrosclerosis.126. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of cerebrovascular diseases.127. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of cerebrovascular discases.128. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prophylaxis and/or treatment of cercbrovascular diseases.129. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of cercbral infarction.130. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for usc with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of cerebral infarction.131. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prophylaxis and/or treatment of cerebral infarction. AMENDED SHEETPCT/JP2004/000861 N132. Use of compound (A) and compound (B) as defined in Claim 72 in the manufacture of a medicament for the prophylaxis and/or treatment of cerebral hemorrhage.133. Use of compound (A) as defined in Claim 72 in the manufacture of a preparation for use with compound (B) as defined in Claim 72 for the prophylaxis and/or treatment of cerebral hemorrhage.134. Use of compound (B) as defined in Claim 72 in the manufacture of a preparation for use with compound (A) as defined in Claim 72 for the prophylaxis and/or treatment of cerebral hemorrhage.135. Use according to any one Claims 72, 75, 78, 81, 84, 87, 90, 93, 96, 99, 102, 105, 108, 111, 114, 117, 121, 124, 127, 130 or 133, wherein the medicament is a pharmaceutical composition comprising compound (A) and compound (B) as active ingredients.136. Use according to any one Claims 73, 74, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 91, 92, 94, 95,97, 98, 100, 101, 103, 104, 106, 107, 109, 110, 112, 113, 115, 116, 118, 119, 121, 122, 124, 125, 127, 128, 130, 131, 133, or 134, whercin the medicament is formulated such that compound (A) and compound (B) arc administrable at the same time or separately at certain intervals.137. Use according to any one Claims 72 to 134, wherein the angiotensin II receptor antagonist is (5-methyl-2-0x0-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy- 1-methylethyl)-2- propyl-1-[{{2’-(1H-tetrazol-5-yl)biphenyl-4-ylJmethyl]imidazol-5-carboxylate.138. Use according to any one Claims 72 to 134, wherein the calcium channel blocker is selected from the group consisting of azelnidipine, amlodipine, benidipine, nitrendipine, manidipine, nicardipine, nifedipine, nisoldipine, cilnidipine, lercanidipine, niguldipine, nimodipine, aranidipine, efonidipine, barnidipine, felodipine, and nilvadipine. AMENDED SHEET :PCT/IP2004/000861 )139. Use according to any one Claims 72 to 134, wherein the calcium channel blocker i is azelnidipine.140. Use according to any one Claims 72 to 134, wherein the angiotensin II receptor antagonist is (5-methyl-2-0xo0-1,3-dioxolen-4-yl)methy!l 4-(1-hydroxy- l-mcthylethyl)-2- propyl-1-[[2’-(1H-tetrazol-5-yl)biphenyl-4-ylJmethyl]-imidazol-5-carboxylate and the calcium channel blocker is azelnidipine.141. Use according to any one Claims 72 to 134, wherein the angiotensin II receptor antagonist is (5-methyl-2-0xo0-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy- I -methylethyl)-2- propyl-1-[[2’-(1H-tetrazol-5-yl)biphenyl-4-ylJmethyl]-imidazol-5-carboxylate and the calcium channel blocker is amlodipine.142. A substance or composition for use in a method of treatment of prevention according to any one of Claims | to 71, substantially as herein described and illustrated.143. Use according to any one of Claims 72 to 141, substantially as herein described and illustrated.144. A substance or composition for a new use in a method of treatment or prevention; or a new use of compound (A) and/or compound (B) as defined in any one of Claims 72 to 141, or pharmacologically acceptable esters thereof and pharmacologically acceptable salts thereof, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003022990 | 2003-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200506076B true ZA200506076B (en) | 2006-05-31 |
Family
ID=36840895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200506076A ZA200506076B (en) | 2003-01-31 | 2005-07-28 | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN1809353B (en) |
NO (1) | NO334451B1 (en) |
UA (1) | UA82216C2 (en) |
ZA (1) | ZA200506076B (en) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5616599A (en) * | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
US5492904A (en) * | 1991-05-15 | 1996-02-20 | E. I. Du Pont De Nemours And Company | Composition of angiotensin-II receptor antagonists and calcium channel blockers |
-
2004
- 2004-01-29 UA UAA200507589A patent/UA82216C2/en unknown
- 2004-01-29 CN CN200480008667.0A patent/CN1809353B/en not_active Expired - Lifetime
-
2005
- 2005-07-28 ZA ZA200506076A patent/ZA200506076B/en unknown
- 2005-08-30 NO NO20054020A patent/NO334451B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
UA82216C2 (en) | 2008-03-25 |
CN1809353A (en) | 2006-07-26 |
NO20054020D0 (en) | 2005-08-30 |
NO20054020L (en) | 2005-10-27 |
CN1809353B (en) | 2010-05-05 |
NO334451B1 (en) | 2014-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080176909A1 (en) | Methods for prevention and treatment of arteriosclerosis, hypertension and restenosis | |
JP5148296B2 (en) | Angiotensin II receptor antagonist and pharmaceutical composition containing calcium antagonist | |
US20190175551A1 (en) | Medicine for treating renal disease | |
US20030166699A1 (en) | Use of angiotensin II receptor antagonists for treating acute myocardial infarction | |
WO2009145358A2 (en) | Medicament for the prophylaxis or treatment of hypertension | |
ZA200506076B (en) | Medicine for prevention of and treatment for arteriosclerosis and hypertension | |
JP5100039B2 (en) | Pharmaceuticals for the prevention and treatment of arteriosclerosis and hypertension | |
CA2522318C (en) | Drug for preventing or treating angiogenic eye diseases | |
US20120302614A1 (en) | Method for improving cerebral circulation or treating a cerebral blood flow disorder | |
RU2261708C2 (en) | Pharmaceutical composition |